Rigel Pharmaceuticals | RIGL - Operating Profit


Rigel Pharmaceuticals reported $14.06M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Agenus USD 14.4M 19.26M Dec/2025
Amgen USD 3.83B 130M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celldex Therapeutics USD -84.44M 2.72M Mar/2026
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Ligand Pharmaceuticals USD 60.33M 40.29M Mar/2026
MacroGenics USD -12.1M 30.74M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Veracyte USD 19.08M 5.55M Mar/2026